This website has been produced and funded by Novo Nordisk and is
intended for adult patients in the United Kingdom who have been
prescribed Wegovy®▼ (semaglutide injection). Side effect
reporting information can befound in the footer of this page.
This website has been developed by Novo Nordisk UK to provide information to UK-based adult patients prescribed Wegovy®.
The information on this website does not replace the patient information leaflet, which you are advised to read in full. It is not intended as a substitute for clinical advice provided by your healthcare professional. Please contact your healthcare professional if you have any questions about your treatment and for clinical advice.
To ensure you receive the information that meets your needs, please tell us who you are:
I am a member of the public based in the United Kingdom →
I am a healthcare professional or other relevant decision maker based in the United Kingdom →
I am an adolescent patient aged 12–17 years old who has been prescribed Wegovy® or their carer →
Reporting side effects
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information promptly. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at
https://yellowcard.mhra.gov.uk/. Side effects should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes. By reporting side effects, you can help provide more information on the safety of this medicine.